Zevra Therapeutics (NASDAQ:ZVRA) Rating Lowered to Buy at Wall Street Zen

Wall Street Zen cut shares of Zevra Therapeutics (NASDAQ:ZVRA - Free Report) from a strong-buy rating to a buy rating in a research note issued to investors on Sunday.

A number of other brokerages have also recently commented on ZVRA. HC Wainwright assumed coverage on Zevra Therapeutics in a research report on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price target on the stock. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Finally, Cantor Fitzgerald lifted their target price on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $23.71.

Zevra Therapeutics Trading Down 4.7%

Zevra Therapeutics stock traded down $0.59 during trading hours on Friday, reaching $12.07. The stock had a trading volume of 1,200,309 shares, compared to its average volume of 738,236. The stock has a market cap of $659.99 million, a PE ratio of -6.35 and a beta of 1.97. Zevra Therapeutics has a 52 week low of $5.45 and a 52 week high of $13.16. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.02 and a quick ratio of 2.93. The company has a fifty day simple moving average of $9.54 and a 200-day simple moving average of $8.35.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. The firm had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. During the same quarter in the previous year, the firm posted ($0.40) EPS. Analysts forecast that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Zevra Therapeutics

Hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new position in shares of Zevra Therapeutics in the fourth quarter worth approximately $53,000. GAMMA Investing LLC grew its stake in Zevra Therapeutics by 20,564.1% during the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock valued at $60,000 after acquiring an additional 8,020 shares in the last quarter. Strs Ohio purchased a new position in Zevra Therapeutics during the first quarter valued at $125,000. Squarepoint Ops LLC grew its stake in Zevra Therapeutics by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after acquiring an additional 4,384 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new position in Zevra Therapeutics during the fourth quarter valued at $145,000. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.